␤A4-Amyloid peptide, the main component of the amyloid plaques in the brain of Alzheimer's disease patients is produced from amyloid precursor protein (APP) by proteolytical processing. Several lines of evidence suggest a direct role for cathepsin D, the major endosomal/ lysosomal aspartic endopeptidase, in ␤A4-amyloid peptide generation. Here we tested this hypothesis using primary cultures of hippocampal neurons derived from cathepsin D-deficient (knock out) mice and expressing wild-type human APP and two clinical APP variants via recombinant Semliki Forest virus. We demonstrate APP secretory processing, production of carboxyl-terminal amyloid fragments, and secretion of the ␤A4-amyloid peptide in the complete absence of cathepsin D. The results rule out cathepsin D as a critical component of ␣-, ␤-, or ␥-secretase and therefore as a primary target for drugs aimed at decreasing the ␤A4-amyloid peptide burden in Alzheimer's disease.
A distinguishing feature of Alzheimer's disease (AD) 1 is the deposition of amyloid plaques in the brain, which arise by abnormal accumulation of ␤A4 peptide (1) . The 39 -43-residue ␤A4 peptide is derived from a 695-residue amyloid precursor protein (APP) by proteolytic processing (2) . APP is a type I integral membrane protein expressed by many cell types in vitro and in vivo, in particular by neurons (3) . After synthesis in the endoplasmic reticulum and complex glycosylation in the Golgi apparatus, APP is processed by an ␣-secretase into a large secreted fragment representing the ectodomain of APP (APP s ) and a membrane-associated (␣-) carboxyl-terminal stub (4, 5) . ␣-Secretase is active in the late Golgi, in transport vesicles, and at the cell surface (6 -12) . It cleaves the amyloid peptide between Lys-612 and Leu-613 (numbering as in APP695) and precludes therefore further amyloid formation (13) . APP that escapes ␣-secretase cleavage is transported as an integral membrane protein to the cell surface, endocytosed, and degraded in the endosomes and lysosomes (10 -12, 14) . In the endosomes, but possibly also in the secretory pathway, a ␤-secretase cleaves APP specifically between Met-596 and Asp-597 at the amino terminus of the ␤A4 peptide, resulting in a membrane-bound (␤-)carboxyl-terminal stub (10, 15, 16) . A ␥-secretase, whose subcellular localization is unknown, cleaves these membrane-associated stubs between amino acid residues Val-635 and Thr-639 at the carboxyl terminus of the ␤A4 peptide (14) . Thus, the ␤A4 peptide is the product of combined ␤-and ␥-secretase activity. The identification of the secretases is a major goal of AD research since drugs that inhibit either ␤-or ␥-secretase or stimulate ␣-secretase, could decrease the production of amyloid peptide in AD brain.
Accumulating evidence has implicated cathepsin D as the ␤-or ␥-secretase involved in the amyloidogenic processing of APP (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . This aspartyl proteinase is present in all mammalian species and is expressed in most tissues (18, 29 -32) . It has been detected in lysosomes and in endosomes, where ␤A4 peptide production is believed to occur (10 -12, 14, 16) . Aspartyl proteinases are involved in the generation of amyloidogenic APP fragments in cells cultured in vitro (23) . Cathepsin D mRNA (17, 19) and cathepsin D-enzyme activity (20) is up-regulated in brains of AD patients, and cathepsin D is present in amyloid plaques (17, 19, 26) . Cathepsin D was identified as the major APP-processing activity in brain extracts of Alzheimer's patients (24, 25) . The hundredfold enhancement of cleavage of a synthetic substrate containing the Swedish APP mutation by human brain extracts and by purified cathepsin D (27) , and the inhibition of APP cleavage by the aspartyl proteinase inhibitor pepstatin A (26, 27) are further hints as to a contribution of cathepsin D in APP processing. Furthermore, it was shown that cathepsin D is unable to degrade the ␤A4 1-42 peptide (27) . While accumulating evidence based on immunological, chromatographic, and enzymatic data seems thus to support strongly the role of cathepsin D in APP processing, direct evidence is lacking.
We have recently generated cathepsin D-deficient mice (32) . These mice develop normally during embryogenesis but die invariably around day 25 after birth from a syndrome characterized by massive intestinal necrosis, thromboembolia, and lymphopenia (32) . Bulk degradation of protein in lysosomes of cathepsin DϪ/Ϫ fibroblasts is not significantly altered, indicating that the essential function of cathepsin D is limited proteolysis of biologically active peptides such as growth factors important for the turnover of epithelial and lymphoid cells (32) . In the current study, the question of whether cathepsin D is also involved in limited proteolytic processing of human APP is addressed directly. Human APP and two clinical APP mutants were expressed in primary cultures of hippocampal neurons derived from cathepsin DϪ/Ϫ embryos by infection with recombinant Semliki Forest virus (SFV) (33, 34) . A set of antibodies was used to identify different intermediates of APP metabolism in these cells.
MATERIALS AND METHODS
Neuronal Cell Culture-Hippocampal neurons were prepared from E17 mice embryos from cathepsin Dϩ/Ϫ heterozygote crosses as described (35) . Every embryo was dissected individually. The obtained hippocampi were dissociated by trypsinization, cells were plated on polylysine-coated plastic dishes (6 cm, Nunc). Cells were maintained in neurobasal medium containing B27 supplement (Life Technologies, Inc.). Proliferation of non-neuronal cells was prevented by adding 5 M cytosine arabinoside. Genomic DNA was prepared from the remaining embryo tissues and used for genotyping of the cultures. Cathepsin D-exon 4 specific PCR with primers MCD14 (5Ј-AGACTAACAGGCCT-GTTCCC-3Ј) and MCD15 (5Ј-TCAGCTGTAGTTGCTCACATG-3Ј) amplified a 200-bp fragment in the wild-type allele and a 1400-bp fragment in the cathepsin D-mutant allele due to the insertion of the neomycin cassette (32) . A neomycin cassette insert-specific PCR was performed in parallel using primers AK30 (5Ј-CGGATCAAGCGTATGCAGCCG-3Ј) and AK31 (5Ј-CAAGATGGATTGCACGCAGG-3Ј). A missing amplification product indicated the wild-type (ϩ/ϩ) genotype. All genotypes were confirmed by Southern blot analysis (32) .
Semliki Forest Virus Infection, Metabolic Labeling, and Double Immunoprecipitation-The preparation of the recombinant SFV stocks has been described previously (33, 34) . Virus was diluted in conditioned culture medium and added to 5-day-old neurons. After viral adsorption (1 h), the virus solution was replaced by normal conditioned culture medium. After 2 h, methionine-free N2-medium containing 200 Ci/ml [ 35 S]methionine was added to the neurons. Cell extracts and culture supernatants were processed 3 h later as described previously (33, 34) . Antibodies were added, and immune complexes were recovered with protein G-Sepharose. Immunoprecipitated material was denatured by boiling in electrophoresis buffer containing 1% SDS and 1% ␤-mercaptoethanol and analyzed on 6% Tris-glycine or 10 -20% Tris-Tricine SDS-polyacrylamide gels (Novex). Gels were impregnated with Intensify (DuPont NEN), dried, and exposed for 1-14 days to Kodak XAR film.
Antibodies-All antibodies used in the current study have been described previously. Anti-APP675-695 (numbering as in APP695) was raised against the 20 carboxyl-terminal amino acid residues of APP (previously B12/4 (33)). Anti-APP1-612 was raised against purified APP s (Ab207 (36)). Anti-APP597-612 (B7/6 (33, 34)) and anti-APP597-638 (Ab692 (34)) were raised against the human ␤A4-amyloid peptide. Anti-APP/NL595-596 (Ab54 (11)) was raised against peptide CSEVNL and recognizes specifically the amino acid substitutions in the "Swedish" mutant APP. 2 Quantitative Densitometry-The densities of the ␤-amyloid peptide bands in the autoradiographies were calculated by volume integration using a personal densitometer (Molecular Dynamics, Inc., Sunnyvale, CA). The absolute volumes (in arbitrary units) were converted toward relative volumes by normalization toward the volumes obtained for APP holoprotein immune-precipitated from the cell extracts of the same experiment. This compensated for differences in expression levels and cell numbers between the separate neuronal cell cultures. The following formula was used to compare production of ␤A4-amyloid peptide in every pair of cathepsin DϪ/Ϫ and cathepsin Dϩ/ϩ neuronal cell cultures: ((␤-amyloid peptide from cathepsin DϪ/Ϫ culture) ϫ (APP holoprotein from cathepsin Dϩ/ϩ culture))/((␤-amyloid peptide from cathepsin Dϩ/ϩ culture) ϫ (APP holoprotein from cathepsin DϪ/Ϫ culture)). Only cultures from littermate embryos that were prepared, cultured, infected, and processed in parallel have been used for the calculations. Under "Results and Discussion," the means Ϯ S.E.M. of the indicated number (n) of such experiments are given.
RESULTS AND DISCUSSION
Cathepsin D-deficient Hippocampal Neurons-Cathepsin Ddeficient homozygous mice (cathepsin DϪ/Ϫ) are not fertile (32) . Therefore, primary cultures of hippocampal neurons were established from individual E17 mouse embryos produced by heterozygous matings of mice with one defective cathepsin D gene allele (32) . The genotype of every culture was tested by PCR (Fig. 1A) and confirmed by Southern blot analysis (Fig.  1B) as detailed under "Materials and Methods." The absence of cathepsin D protein was demonstrated by immunoprecipitation using cathepsin D antibodies (Fig. 1C) .
Wild-type Human APP Processing-A set of previously characterized specific APP antibodies, summarized in Fig. 2A , was used to analyze the metabolism of APP in recombinant SFVinfected cathepsin Dϩ/ϩ and cathepsin DϪ/Ϫ hippocampal neurons derived from littermate embryos. Uncleaved integral membrane APP was readily expressed in the neurons (Fig. 2B , a) and processed to soluble APP s , which was secreted into the culture medium (Fig. 2B, d) . APP s isolated from the cathepsin Dϩ/ϩ and from the cathepsin DϪ/Ϫ neuronal cultures migrated as a doublet band in SDS-polyacrylamide gel electrophoresis due to different levels of sialic acid content (34) . The doublet bands are produced by ␣-secretase and react with amino-terminal and carboxyl-terminal specific antibodies (34) . Importantly, cathepsin DϪ/Ϫ and cathepsin Dϩ/ϩ neurons secreted ␤A4-amyloid peptide (Fig. 2B, e) which clearly demonstrated that even in the complete absence of cathepsin D, amyloidogenic processing of wild type APP occurred. Quantitative differences in the APP fragments immunoprecipitated from cathepsin Dϩ/ϩ and cathepsin DϪ/Ϫ cultures could fully be accounted for by variations in expression levels of APP in the individual cultures. This was assessed converting the absolute densities of the ␤A4-amyloid peptide bands in the autoradiographies toward relative ones by normalization using the densities of the APP holoprotein bands. It was found that cathepsin DϪ/Ϫ neurons produced similar relative amounts of ␤A4-amyloid peptide as the cathepsin Dϩ/ϩ neurons (1.16 Ϯ 0.09, n ϭ 3; see "Materials and Methods" for the formula used).
That cathepsin DϪ/Ϫ neurons displayed authentic ␣-and ␤-secretase was independently confirmed by immunoprecipitating the corresponding carboxyl-terminal stubs from the cell extracts (Fig. 2B, b) . These fragments have previously been characterized by radioactive sequencing (34) . The identity of the ␤-cleaved membrane-associated fragment was further corroborated using anti-APP597-612 antiserum (33, 34) . This antiserum reacts specifically with epitopes between the ␤-and the ␣-cleavage site in the ␤A4 sequence and therefore only immunoprecipitated the ␤-cleaved stubs (Fig. 2B, c) . The obtained fragment comigrated with the protein band indicated by ␤ in Fig. 2B, b (result not shown) . The mobility and the relative amounts of both the ␣-and the ␤-stubs were identical in cathepsin Dϩ/ϩ and Ϫ/Ϫ neurons, confirming that cathepsin D is not essential for ␣-and ␤-secretase processing of APP in neurons. It should be mentioned that a previously reported "␦"-cleaved carboxyl-terminal fragment was not detected in the mouse hippocampal neurons (33, 34) . This fragment is a constant finding in rat hippocampal neurons and represents an intermediate of APP catabolism in that species. 3 
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FIG. 1. Identification of cathepsin D-deficient hippocampal neurons.
A, PCR analysis of tissues from E17 embryos of heterozygote cathepsin D ϩ/Ϫ crosses. Cathepsin D-exon 4 (CTSD-exon4)-specific PCR amplifies a 200-bp fragment in the wild-type allele. In the cathepsin D mutant allele, this fragment is replaced by a 1400-bp fragment due to the insertion of the neomycin cassette (32) . Insertion of the neomycin cassette is confirmed by a 387-bp amplification product in the neomycin-specific PCR (Neo-cassette). B, Southern blot analysis of tissues from E17 embryos of cathepsin Dϩ/Ϫ crosses. DNA was digested with BglII and analyzed by Southern blotting with external probe B (32) . C, immunoprecipitation of cathepsin D from homogenates of hippocampal neurons with cathepsin D-specific rabbit polyclonal antiserum (45) .
sin DϪ/Ϫ Neurons-Since it has been claimed that synthetic peptides containing the Swedish mutation of APP are cleaved particularly efficiently by cathepsin D (27) , processing of this clinical mutant was studied in further detail. The Swedish mutation consists of a double point mutation replacing Lys-595 by Asn and Met-596 by Leu (Ref. 37, Fig. 2A ) which causes increased ␤A4-peptide secretion (38, 39) . The mutation provides a better substrate for a ␤-secretase that is possibly different from the ␤-secretase that cleaves wild type APP and is active in an early compartment of the biosynthetic pathway, presumably the cis-Golgi (10 -12, 40) . The early cleavage of the Swedish APP mutant results in partial missorting of the APP ectodomain in polarized Madin-Darby canine kidney cells (41, 42) . Since this type of cleavage presumably precedes or competes for the ␣-secretase cleavage, high amounts of ␤-cleaved fragments are produced in neurons expressing this clinical mutant (33) . This is confirmed here in cathepsin Dϩ/ϩ neurons and, importantly, in cathepsin DϪ/Ϫ neurons demonstrating that the same "early" ␤-secretase was operational in cathepsin DϪ/Ϫ neurons (Fig. 3A, b) . That the ␤-cleavage of the Swedish APP mutant occurred exactly at the predicted position, i.e. after the double mutation, was further corroborated using anti-APP/NL595-596, which specifically recognizes the two mutated amino acid residues Asn-Leu ( Fig. 2A) . This antibody (13, 14) precipitated ␤-cleaved APP s from the culture medium (Fig.  3A, e) independently confirming authentic ␤-secretase activity in the cathepsin DϪ/Ϫ cells. The specificity of this fragment and of the antibody was demonstrated by the absence of immunoreactivity in APP-wild type expressing neurons (data not shown). Finally, similar levels of ␤A4 peptide secretion were observed in cathepsin DϪ/Ϫ and ϩ/ϩ cultures (Fig. 3A, f) . Densitometric scanning of the ␤A4 peptide signals and normalization of the obtained values to the expression levels of APP confirmed again that cathepsin DϪ/Ϫ neurons secreted ␤A4-peptide to the same extent as cathepsin Dϩ/ϩ neurons (1.11 Ϯ 0.10, n ϭ 2).
We finally investigated the production of APP fragments in cell extracts and culture medium of neurons expressing the "London" APP mutant. This mutant contains a single point mutation of Val-642 to Ile and affects the ␥-cleavage of APP resulting in the production of a longer, more amyloidogenic form of the ␤A4 peptide (43, 44) . In cathepsin D-deficient hippocampal neurons, again no decrease in ␤A4 secretion or change in processing of London APP was observed when compared to wild-type control neurons (0.92 Ϯ 0.01, n ϭ 2). This 
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confirms that cathepsin D has also no role in the processing of this clinical APP mutant (Fig. 3B) . ␤A4-Amyloid Production in Cathepsin DϪ/Ϫ Neurons-The evidence for normal ␣-and ␤-secretase activity in the cathepsin DϪ/Ϫ neurons is direct and based on the detection of normal levels of ␣-and ␤-cleaved APP s in the culture medium and the demonstration of authentic ␣-and ␤-cleaved fragments in the cell extracts. Membrane-associated, ␥-secretase-cleaved carboxyl-terminal fragments were not detected in the neuronal cell culture as it was used here, probably because of their rapid turnover. ␤A4-amyloid peptide secretion in the culture medium is, however, the result of combined ␤-and ␥-secretase activity. If cathepsin D is the ␥-secretase, than ␤A4-amyloid secretion in cathepsin DϪ/Ϫ neurons should be decreased. Similar levels for the amount of ␤A4-peptide produced in cathepsin DϪ/Ϫ neurons relative to wild-type neurons (1.08 Ϯ 0.06; n ϭ 7) were obtained, implying that cathepsin D is not a ␥-secretase. Conclusion-Transient expression of human wild-type and mutant APP by recombinant SFV infection of primary cultures of hippocampal neurons derived from knock out mice deficient in the candidate secretase cathepsin D has allowed us to rule out cathepsin D as a critical component of the proteolytic machinery generating secreted ␤A4-amyloid peptide (24 -27) . Since up-regulation of cathepsin D is an early and fairly specific observation in AD brain (17, 19 -22, 28) , it seems likely that cathepsin D has a role in the neurodegenerative process. Our data demonstrate, however, that this enzyme is dispensible for amyloid production, which essentially rules out cathepsin D as a primary target for drugs aimed at decreasing the amyloid production in AD brains. Our results further show that in vitro paradigms to demonstrate secretase activity have to be interpreted with caution. Experiments in intact, living cells are needed to confirm whether an enzyme is really involved in APP processing and is therefore indeed a candidate secretase.
